Avanos Medical (NYSE:AVNS) Shares Gap Down – Should You Sell?

Avanos Medical, Inc. (NYSE:AVNS)’s share price gapped down prior to trading on Tuesday . The stock had previously closed at $15.23, but opened at $14.21. Avanos Medical shares last traded at $13.5510, with a volume of 122,699 shares trading hands.

Analyst Upgrades and Downgrades

Several brokerages have commented on AVNS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Avanos Medical in a report on Monday, December 22nd. Wall Street Zen raised shares of Avanos Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Finally, Zacks Research upgraded shares of Avanos Medical from a “strong sell” rating to a “hold” rating in a research note on Monday, January 26th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Reduce”.

Avanos Medical Stock Performance

The stock has a 50 day moving average price of $12.86 and a two-hundred day moving average price of $12.02. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.38 and a quick ratio of 1.36. The company has a market capitalization of $640.35 million, a price-to-earnings ratio of -1.35 and a beta of 1.09.

Avanos Medical (NYSE:AVNS) last released its earnings results on Tuesday, February 24th. The company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.24 by $0.05. The company had revenue of $180.90 million during the quarter, compared to analysts’ expectations of $174.70 million. Avanos Medical had a positive return on equity of 6.21% and a negative net margin of 67.00%.The business’s revenue for the quarter was up .7% on a year-over-year basis. During the same period last year, the firm earned $0.43 EPS. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS. On average, analysts predict that Avanos Medical, Inc. will post 1.32 EPS for the current fiscal year.

Institutional Investors Weigh In On Avanos Medical

Several large investors have recently bought and sold shares of AVNS. EverSource Wealth Advisors LLC grew its position in Avanos Medical by 132.6% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,496 shares of the company’s stock valued at $28,000 after purchasing an additional 1,423 shares in the last quarter. Versant Capital Management Inc boosted its position in shares of Avanos Medical by 49.7% in the third quarter. Versant Capital Management Inc now owns 2,692 shares of the company’s stock valued at $31,000 after acquiring an additional 894 shares during the period. Russell Investments Group Ltd. boosted its position in shares of Avanos Medical by 969.3% in the second quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company’s stock valued at $31,000 after acquiring an additional 2,307 shares during the period. Wexford Capital LP acquired a new position in shares of Avanos Medical in the third quarter valued at about $70,000. Finally, Tower Research Capital LLC TRC increased its position in Avanos Medical by 433.0% during the second quarter. Tower Research Capital LLC TRC now owns 6,257 shares of the company’s stock worth $77,000 after acquiring an additional 5,083 shares during the period. Institutional investors own 95.17% of the company’s stock.

About Avanos Medical

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.